Last $15.60 USD
Change Today +1.06 / 7.29%
Volume 1.9M
As of 12:18 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Snapshot

Open
$14.40
Previous Close
$14.54
Day High
$15.83
Day Low
$14.10
52 Week High
10/24/14 - $15.83
52 Week Low
05/9/14 - $5.40
Market Cap
676.9M
Average Volume 10 Days
3.5M
EPS TTM
$-0.73
Shares Outstanding
43.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGULUS THERAPEUTICS INC (RGLS)

regulus therapeutics inc (RGLS) Related Businessweek News

View More BusinessWeek News

regulus therapeutics inc (RGLS) Details

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which is chemically modified and single-stranded oligonucleotide. Its clinical candidate products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection. The company has strategic collaboration with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GlaxoSmithKline plc to discover and develop microRNA therapeutics for immuno-inflammatory diseases. It also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 pre-clinical fibrosis program for the treatment of alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

81 Employees
Last Reported Date: 08/7/14
Founded in 2007

regulus therapeutics inc (RGLS) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $600.0K
Chief Scientific Officer
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

regulus therapeutics inc (RGLS) Key Developments

Regulus Therapeutics Announces Positive Interim Results of RG-101 for Treatment of Hepatitis C Virus Infection

Regulus Therapeutics (RGLS) provided interim results from an ongoing clinical study on RG-101, a wholly-owned GalNac-conjugated anti-miR targeting microRNA-122, for the treatment of hepatitis C virus infection. The company announced that treatment with a single subcutaneous dose of 2mg/kg of RG-101 resulted in significant and sustained reductions in HCV RNA in a varied group of patients and that the drug was safe and well tolerated and has demonstrated a very favorable pharmacokinetic profile to date, which may allow for combination with oral direct-acting antiviral agents to treat HCV. The company also reported that it plans to file an Investigational New Drug Application with the U.S. Food and Drug Administration in the first quarter of 2015 and plan to initiate a Phase II DAA combination study of RG-101 in HCV patients in the second quarter of 2015. In addition, it looked forward to reporting additional data from the ongoing study in the first half of 2015.

Regulus Therapeutics Inc. - Special Call

To discuss the interim results from the ongoing clinical study of RG-101 for the treatment of HCV

Regulus Therapeutics Inc. Demonstrates Human Proof-Of-Concept with a microRNA Therapeutic

Regulus Therapeutics Inc. announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122, for the treatment of hepatitis C virus infection. Interim results from the ongoing clinical study demonstrate that treatment with a single subcutaneous dose of 2 mg/kg of RG-101 as monotherapy resulted in significant and sustained reductions in HCV RNA in a varied group of patients, including difficult to treat genotypes and patients who experienced viral relapse after a prior IFN-containing regimen. Additionally, RG-101 was safe and well tolerated and has demonstrated a very favorable pharmacokinetic profile to date, which may allow for combination with oral direct-acting antiviral agents to treat HCV. In the first dose cohort of part IV of the ongoing study, 16 HCV patients were enrolled with multiple genotypes, 10 GT1s, 5 GT3s, and 1 GT4. 14 patients, 8 naïve and 6 patients who experienced viral relapse after a prior IFN-containing regimen, received a single subcutaneous dose of 2 mg/kg of RG-101 as monotherapy while 2 patients received placebo. In the 14 HCV treated patients, there was a mean viral load reduction of 4.1 log10 at day 29 (range -5.8 log10 to -2.3 log10). 6 out of 14 patients had HCV RNA levels below the limit of quantification at day 29 and the 3 patients from this group who have reached day 57 still have HCV RNA levels below the limit of quantification. Viral load reduction occurs within the first 96 hours and virologic response is not influenced by IL-28 genotype. Due to the long-lasting and sustained virologic effect seen, the ongoing study protocol has been amended to follow patients for up to six months after dosing to evaluate the possibility for certain patients to achieve viral cure after a single dose of RG-101. There were no drug-drug interactions from part III of the ongoing study in which RG-101 was combined with simeprevir (OLYSIO(TM)), an approved oral DAA (protease inhibitor), and the combination had no effect on the pharmacokinetic profile of RG-101 or simeprevir (OLYSIO(TM)).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $15.60 USD +1.06

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.64 AUD -0.01
Galena Biopharma Inc $1.89 USD 0.00
Prosensa Holding NV $12.03 USD -0.02
Silence Therapeutics PLC 235.00 GBp 0.00
Tekmira Pharmaceuticals Corp C$21.40 CAD -0.92
View Industry Companies
 

Industry Analysis

RGLS

Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 45.2x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 36.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit www.regulusrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.